Athira Pharma Inc. (ATHA): Price and Financial Metrics
ATHA Price/Volume Stats
| Current price | $2.07 | 52-week high | $4.30 |
| Prev. close | $2.04 | 52-week low | $1.33 |
| Day low | $2.07 | Volume | 11,742 |
| Day high | $2.10 | Avg. volume | 386,469 |
| 50-day MA | $2.92 | Dividend yield | N/A |
| 200-day MA | $2.47 | Market Cap | 79.34M |
ATHA Stock Price Chart Interactive Chart >
Athira Pharma Inc. (ATHA) Company Bio
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.
Latest ATHA News From Around the Web
Below are the latest news stories about ATHIRA PHARMA INC that investors may wish to consider to help them evaluate ATHA as an investment opportunity.
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesExploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease, which is on track to complete enrollment in early 2024 and report topline results in second half of 2024 BOTHELL, Wash., Dec. 12, 2023 (GLOBE NEWSWI |
Sidoti Events, LLC's Virtual December Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ... |
Athira Pharma to Participate in Sidoti December Small Cap Investor ConferenceCompany Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s diseaseBOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti Decemb |
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MNDPresentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate f |
ATHA Price Returns
| 1-mo | -18.50% |
| 3-mo | -32.79% |
| 6-mo | 33.55% |
| 1-year | -25.54% |
| 3-year | -88.49% |
| 5-year | N/A |
| YTD | -14.81% |
| 2023 | -23.34% |
| 2022 | -75.67% |
| 2021 | -61.96% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...